Filing Details

Accession Number:
0001209191-21-012204
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-18 20:43:04
Reporting Period:
2021-02-16
Accepted Time:
2021-02-18 20:43:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1347178 Vanda Pharmaceuticals Inc. VNDA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1263499 W Richard Dugan 298 Beacon Circle
Boalsburg PA 16827
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-16 15,000 $7.11 60,641 No 4 M Direct
Common Stock Disposition 2021-02-16 5,754 $18.54 54,887 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-02-16 15,000 $0.00 15,000 $7.11
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2021-06-15 No 4 M Direct
Footnotes
  1. Represents shares of the Issuer's common stock sold to satisfy the exercise price of the stock options, which were scheduled to expire June 15, 2021 as reflected in this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.25 to $18.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. The option vested in 12 equal monthly installments beginning on July 16, 2011.